SEQUENCE LISTING

<110> Ribopharma AG
Kreutzer Dr., Roland
Limmer Dr., Stephan

<120> Method and Medicament for Inhibiting the Expression of a Given Gene

<130> 20200/2093D (400968)

<140> US 10/612,179
<141> 2003-07-02

<150> DE 199 03 713.2
<151> 1999-01-30

<150> DE 199 56 568.6
<151> 1999-11-24

<150> 09/889,802
<151> 2001-09-17

<150> PCT/DE00/00244
<151> 2000-01-29

<160> 8

<170> PatentIn version 3.2

<210> 1
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of the artificial sequence:
EcoRI cleavage site, T7 RNA Polymerase promoter

<400> 1
ggaattctaa tacgactcac tatagggcga tcagatctct agaag 45

<210> 2
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of the artificial sequence:
BamHI cleavage site, SP6 RNA Polymerase promoter

<400> 2
gggatccatt taggtgacac tatagaatac ccatgatcgc gtagtcgata 50

<210> 3

<211> 340
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of the artificial sequence:
RNA which corresponds to a sequence from the positive control DNA of the HeLa Nuclear Extract in vitro transcription kit from Promega

<400> 3
ucagaucucu agaagcuuua augcgguagu uuaucacagu uaaauugcua acgcagucag 60

gcaccgugua ugaaaucuaa caaugcgcuc aucgucaucc ucggcaccgu cacccuggau 120

gcuguaggca uaggcuuggu uaugccggua cugccgggcc ucuugcggga uaucguccau 180

uccgacagca ucgccaguca cuauggcgug cugcuagcgc uauaugcguu gaugcaauuu 240

cuaugcgcac ccguucucgg agcacugucc gaccgcuuug gccgccgccc aguccugcuc 300

gcuucgcuac uuggagccac uaucgacuac gcgaucaugg 340

<210> 4
<211> 363
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of the artificial sequence:
DNA which corresponds to a sequence from the positive control DNA of the HeLa Nuclear Extract in vitro transcription kit from Promega

<400> 4
tcagatctct agaagcttta atgcggtagt ttatcacagt taaattgcta acgcagtcag 60

gcaccgtgta tgaaatctaa caatgcgctc atcgtcatcc tcggcaccgt caccctggat 120

gctgtaggca taggcttggt tatgccggta ctgccgggcc tcttgcggga tatcgtccat 180

tccgacagca tcgccagtca ctatggcgtg ctgctagcgc tatatgcgtt gatgcaattt 240

ctatgcgcac ccgttctcgg agcactgtcc gaccgctttg gccgccgccc agtcctgctc 300

gcttcgctac ttggagccac tatcgactac gcgatcatgg cgaccacacc cgtcctgtgg 360

atc 363

<210> 5
<211> 315
<212> RNA
<213> Artificial Sequence

<220>

<223> Description of the artificial sequence:
Sequence from the YFP gene

<400> 5
auggugagca agggcgagga gcuguucacc gggguggugc ccauccuggu cgagcuggac 60

ggcgacguaa acggccacaa guucagcgug uccggcgagg gcgagggcga ugccaccuac 120

ggcaagcuga cccugaaguu caucugcacc accggcaagc ugcccgugcc cuggcccacc 180

cucgugacca cccugaccua cggcgugcag ugcuucagcc gcuaccccga ccacaugaag 240

cagcacgacu ucuucaaguc cgccaugccc gaaggcuacg uccaggagcg caccaucuuc 300

uucaaggacg acggc 315

<210> 6
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of the artificial sequence:
EcoRI cleavage site, T7 RNA Polymerase promoter, complementary region to the YFP gene

<400> 6
ggaattctaa tacgactcac tatagggcga atggtgagca agggcgagga gc 52

<210> 7
<211> 53
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of the artificial sequence:
BamHI cleavage site, SP6 RNA Polymerase promoter, complementary region to the YFP gene

<400> 7
gggatccatt taggtgacac tatagaatac gccgtcgtcc ttgaagaaga tgg 53

<210> 8
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of the artificial sequence:
RNA which corresponds to a sequence from the YFP gene

<400> 8
ucgagcugga cggcgacgua a 21